Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers suffered another setback when the pharma giant said it would not seek accelerated approval for a combination of two immunotherapy drugs as a treatment for newly diagnosed lung cancer.

Eli Lilly Acquires CoLucid Pharma, Adds Migraine Drug to Pipeline

Eli Lilly Acquires CoLucid Pharma, Adds Migraine Drug to Pipeline

CoLucid will be acquired for $46.50 per share, a 33% premium to the stock's closing price Tuesday.

Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients

Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients

The same Neurocrine drug, valbenazine, is currently under review at the FDA as a treatment for the movement disorder tardive dyskinesia.

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

There are 250 Duchenne patients starting the process to receive reimbursement and treatment with Exondys 51, Sarepta says.

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.